Meet the 2020 Lymphoma Clinical Mentoring Program Scholars
The new class of LRF Scholars is pursuing research projects covering a diverse range of lymphoma subtypes with a goal to improve patient outcomes.
Research News
Bridging the Gap in Adolescent and Young Adult Lymphoma
Dr. Kara Kelly is helping to build the bridge between AYA, and pediatric and adult oncology fields to bring attention to this underserved population and improve patient care.
Lymphoma Research Foundation Funds 16 New Early Career Scientists from World-Leading Cancer Research Institutes
The Lymphoma Research Foundation (LRF) is proud to announce it has awarded 16 grants totaling $1.375 million to early career and disease-specific scientists based at many of the world’s leading cancer research institutes. The 2020 LRF research portfolio includes grants…
Highlights from 2019 American Society Of Hematology (ASH) Meeting
The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with nearly 70 LRF-affiliated scientists presenting more than 100 abstracts at this year’s conference.
Playing the Long Game in Lymphoma Research
Playing the long game is not a new concept for Lymphoma Research Foundation Grantee and Scientific Advisory Board (SAB) member Ari Melnick, MD, of NewYork-Presbyterian/Weill Cornell Medicine. Lymphoma research is not a field for those looking for instant gratification, but Dr. Melnick has never taken a sprinter’s approach to finding cures for lymphoma. He is more of a marathoner.
LRF Grantee and SAB Member Discovers Protein Responsible for Lymphoma Cell Growth
A study partially funded by the Lymphoma Research Foundation, and published in the Journal of Experimental Medicine, revealed surprising new functions for a protein called MYC.
Recent Study Suggests Model to Address Research Gaps and Unmet Needs in Oral Adherence for Lymphoma
Several oral agents have been proven active in the treatment of certain subtypes of non-Hodgkin lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and Waldentröm macroglobulinemia (WM); and for…
Researchers Discover Why Patients’ Lymphoma May Become Resistant to Specific Therapy
In a study funded in part by the Lymphoma Research Foundation, researchers find the loss of specific protein amplification and transcriptional reprogramming contribute to resistance to venetoclax for patients with B-cell lymphomas Researchers from Moffitt Cancer Center and Dana-Farber Cancer…
AUGMENT Trial Demonstrates Promising New Combination for Relapsed/Refractory Indolent Lymphoma
Rituximab (Rituxan) has long been the standard of care for many lymphoma patients with relapsed follicular lymphoma (FL) and marginal zone lymphoma (MZL). Researchers on the AUGMENT trial, a large-scale, multicenter study, sought to improve outcomes for this group of…
New Therapeutic Combination Shows Promise for Relapsed/Refractory Hodgkin Lymphoma
At the 2018 ASH Annual Meeting, Catherine Diefenbach, MD (New York University) – a past recipient of LRF’s Clinical Investigator Career Development Award – presented data from cooperative group ECOG-ACRIN’s clinical trial of a new combination of existing therapies ipilimumab…